Novartis To Step Up Investment In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Swiss drug maker Novartis plans to deepen its investment in China this year despite the West's economic downturn, and will expand its research and development center here while launching new drugs in the Chinese market, according to high-level Novartis executives
You may also be interested in...
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health